Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OGA | O60502 | 12/20 | 0.40 |
| ▸ | SMPD1 | P17405 | 2/20 | 0.40 |
| ▸ | SRD5A1 | P18405 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | SRD5A2 | P31213 | 2/20 | 0.35 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.35 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.34 |
| ▸ | CDK9 | P50750 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14722713 | 0.88 | GPR119 (0.40) | OGASMPD1HDAC2 | |
| SCHEMBL14722832 | 0.85 | OGA (0.38) | OGASMPD1RAB9ASRD5A2 | |
| SCHEMBL14721047 | 0.79 | GPR119 (0.42) | OGASMPD1SRD5A1HDAC2 | |
| SCHEMBL14720688 | 0.76 | GPR119 (0.41) | OGASMPD1HDAC2 | |
| SCHEMBL28098574 | 0.71 | GSK3B (0.51) | SRD5A1RAB9AHDAC2 | |
| SCHEMBL14720576 | 0.69 | SRD5A1 (0.52) | OGASRD5A1SRD5A2HDAC2 | |
| SCHEMBL14722165 | 0.68 | SRD5A1 (0.51) | OGASRD5A1SRD5A2HDAC2 | |
| SCHEMBL14720706 | 0.68 | SRD5A1 (0.51) | OGASRD5A1SRD5A2HDAC2 | |
| SCHEMBL14720755 | 0.67 | HRH3 (0.40) | RAB9A | |
| SCHEMBL22683282 | 0.67 | SRD5A1 (0.50) | OGASRD5A1SRD5A2HDAC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2013027001-A1 | COMPOUNDS AND THEIR USE TO TREAT HISTAMINE H3 RELATED DISORDERS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-02-28 | — | — | WO | disclosed |